Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer
NCT03086642
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Cancer
Interventions
DRUG:
Talimogene laherparepvec
Sponsor
Karie D. Runcie, MD
Collaborators
[object Object]